These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31236779)

  • 1. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
    Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
    Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction.
    Huang H; Shi Y; Liang B; Cai H; Cai Q; Lin R
    Clin Endocrinol (Oxf); 2018 Mar; 88(3):473-478. PubMed ID: 29288501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
    Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
    Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
    Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
    Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
    Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
    Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
    Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High neutrophil-to-lymphocyte ratio is associated with relapse in Graves' disease after antithyroid drug therapy.
    Kim M; Kim BH; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
    Endocrine; 2020 Feb; 67(2):406-411. PubMed ID: 31749116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism.
    Weng H; Tian WB; Xiao ZD; Xu L
    Arch Endocrinol Metab; 2023 May; 67(4):e000609. PubMed ID: 37252698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
    Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
    Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Anti-Thyroid Medications in Patients with Graves' Disease.
    Mahzari MM; Alanazi MM; Alabdulkareem YM; Alharbi WA; Alzahrani AS; Alqahtani NA; Ajwah IM; Ardah HI
    BMC Endocr Disord; 2024 Sep; 24(1):180. PubMed ID: 39237901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease.
    Azizi F; Mehran L; Abdi H; Amouzegar A
    J Clin Endocrinol Metab; 2024 Sep; 109(10):e1881-e1888. PubMed ID: 39018185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse following antithyroid drug therapy for Graves' hyperthyroidism.
    Laurberg P; Krejbjerg A; Andersen SL
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):415-21. PubMed ID: 25111942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
    Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
    Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
    Choi YM; Kwak MK; Hong SM; Hong EG
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
    Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
    J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
    Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.
    Song A; Kim SJ; Kim MS; Kim J; Kim I; Bae GY; Seo E; Cho YS; Choi JY; Cho SY; Jin DK
    Front Endocrinol (Lausanne); 2021; 12():687834. PubMed ID: 34194397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.